Welcome to our dedicated page for Palatin Tech SEC filings (Ticker: PTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palatin Technologies, Inc. (PTN) SEC filings page on Stock Titan provides direct access to the company’s official regulatory disclosures, along with AI-assisted context to help interpret them. As a biopharmaceutical issuer focused on melanocortin receptor–based therapeutics, Palatin uses filings such as Form 8-K, proxy statements, and registration statements to report material events, governance matters, and financing activities.
Investors can review Form 8-K reports detailing key corporate developments, including NYSE American delisting notices and appeals, the transition of trading to OTC markets, the implementation of a 1-for-50 reverse stock split, and the subsequent resumption of trading on NYSE American under the PTN symbol. Other 8-K filings describe material agreements, such as the Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for melanocortin receptor–targeted peptides in retinal diseases, outlining upfront payments, research milestones, and potential development and commercial milestones.
Palatin’s DEF 14A proxy statement and related filings provide information on annual meeting items, including director elections, amendments to the restated certificate of incorporation to effect a reverse stock split, ratification of the independent registered public accounting firm, approvals of warrant-related share issuances, and amendments to the company’s equity incentive plan. These documents also cover advisory votes on executive compensation and the frequency of future say-on-pay votes.
Through this page, users can also locate registration statements referenced in Palatin’s press releases for public offerings, which describe the terms of common stock and warrant issuances used to fund development of its obesity and other programs. Stock Titan’s interface surfaces these filings as they are posted to EDGAR and applies AI-powered summaries to highlight the sections most relevant to PTN—such as capital structure changes, collaboration economics, and listing status updates—so readers can more quickly understand the implications of each document without reading every page in full.
Palatin Technologies reported a larger quarterly loss but a stronger balance sheet in its quarter and six months ended December 31, 2025. Collaboration and license revenue reached $8.96 million for the six-month period, all from a new agreement with Boehringer Ingelheim, compared with no revenue a year earlier.
The company posted a net loss of $7.26 million for the quarter and $2.59 million for six months, narrower than the prior-year six‑month loss. Cash and cash equivalents rose to $14.48 million, up from $2.56 million at June 30, 2025, helped by multiple equity and warrant financings.
Palatin continues to invest heavily in melanocortin receptor programs for obesity and inflammatory diseases while transitioning prior assets to partners. Management expects existing cash to fund operations for at least 12 months after the statements’ issuance but acknowledges the need for substantial additional funding to advance its pipeline.
Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of 166,713 shares of Palatin Technologies, Inc. common stock, representing 9.79% of the class as of 12/31/2025. Driehaus has shared power to vote and dispose of all these shares, with no sole voting or dispositive power.
The shares are held in fully discretionary accounts for investment advisory clients, including Driehaus Life Sciences Master Fund, L.P., which retain the right to receive dividends and sale proceeds. Driehaus certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Palatin.
Palatin Technologies, Inc. reported insider equity tax-withholding transactions by an executive vice president and CFO/COO. On December 30, 2025, the officer had small amounts of common stock withheld by the company to cover employee withholding taxes tied to previously vested equity grants.
The filing shows three transactions coded "F" at a per-share value of $21.38, withholding 26, 91, and 95 shares from grants of 95, 330, and 345 shares that vested on December 8, 2025. After these tax-related withholdings, the officer reported beneficial ownership of 63,462, 63,371, and 63,276 shares of Palatin common stock in successive entries, all held directly.
Palatin Technologies, Inc. insider Carl Spana, who serves as President, CEO, and director, reported routine tax-related share withholding transactions. On December 30, 2025, the company withheld 40, 138, and 143 shares of common stock, all coded as transaction type “F,” to cover employee withholding taxes tied to previously vested equity awards. The per-share value used for these tax withholdings was $21.38, determined as of December 8, 2025, the vesting date of the underlying grants. After these transactions, Spana directly beneficially owned 64,377 shares of Palatin common stock.
Palatin Technologies, Inc. executive vice president and CFO/COO Stephen T. Wills reported a small sale of company stock. On 12/24/2025, he sold 565 shares of Palatin common stock at a price of $16.7443 per share, in a transaction described as being for estate planning purposes. After this sale, he beneficially owned 63,488 shares, held directly.
A holder of PTN common stock filed a Rule 144 notice to sell 565 shares through Charles Schwab on or about 12/24/2025 on the NYSE Amex. The aggregate market value for these shares is reported as $9,460.53, while total common shares outstanding are listed as 1,702,675. The shares to be sold were originally acquired on 03/04/2011 as stock grants from the issuer as equity compensation, with full payment made in the form of equity compensation on the same date.
Palatin Technologies, Inc. filed an amended current report to update the outcome of a governance-related item from its 2025 annual stockholder meeting. Stockholders voted, on an advisory and non-binding basis, to hold future advisory votes on executive compensation every year, consistent with the Board of Directors’ recommendation.
In response, the Board has decided to include an annual advisory vote on the compensation of the company’s named executive officers in its proxy materials each year, until the next required stockholder vote on how often these advisory votes should occur.
Palatin Technologies executive Stephen T. Wills, who serves as Executive VP and CFO/COO, reported the vesting of performance-based equity awards on December 9, 2025 under the company’s 2011 Stock Incentive Plan. He acquired 95, 330, and 345 restricted share units of common stock at a price of $0 per share as certain performance conditions were certified by the Compensation Committee. These restricted share units each represent the right to receive one share of common stock, with the shares to be issued on or before the 60th day following December 9, 2025.
On the same date, Wills also acquired performance-based stock options to buy Palatin common stock: 142 options with a $362.5 exercise price expiring on June 22, 2032, 518 options with a $109.5 exercise price expiring on June 20, 2033, and 495 options with a $91.5 exercise price expiring on June 4, 2034. Following these transactions, he directly beneficially owned 64,053 shares of common stock and 122,913 derivative securities in the form of stock options.
Palatin Technologies, Inc. director equity grant disclosure: A Palatin Technologies director reported receiving two stock option grants on December 9, 2025 under the company’s 2011 Stock Incentive Plan. Each option is a right to buy 2,400 shares of common stock at an exercise price of $21.38 per share, with both grants expiring on December 9, 2035.
One option grant vests on December 9, 2026, but if the director does not serve through December 31, 2026, it is prorated at 1/12 per month from January 31, 2026. The second option grant vests as to 50% on December 9, 2026 and the remaining 50% on December 9, 2027. Following these grants, the director beneficially owns 5,927 derivative securities in the form of stock options, all held directly.
Palatin Technologies, Inc. reported equity compensation changes for its President and CEO, who is also a director, in a Form 4 insider filing. On December 9, 2025, several performance-based restricted stock unit (RSU) awards granted under the 2011 Stock Incentive Plan partially vested after the Compensation Committee certified that a defined performance objective for the 18 months ending December 31, 2025 was achieved at 100% of the target level.
The vesting resulted in accruals of 110, 380, and 395 common shares at a stated price of $0 per share, bringing the reporting person’s beneficial ownership of common stock to 64,698 shares. The company states these shares have not yet been issued but will be delivered on or before the 60th day following December 9, 2025.
On the same date, three tranches of performance-based stock options also vested in part: 163 options at an exercise price of $362.5, 595 options at $109.5, and 568 options at $91.5, each for common stock, with expirations ranging from June 22, 2032 to June 4, 2034. Following these transactions, the reporting person held 123,939 stock options in total.